Get the Stockscreener App
27.13
1.34%
0.36
After Hours:
27.13
Celldex Therapeutics Inc stock is traded at $27.13, with a volume of 1.10M.
It is up +1.34% in the last 24 hours and up +10.96% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$26.77
Open:
$24.87
24h Volume:
1.10M
Relative Volume:
0.92
Market Cap:
$1.80B
Revenue:
$5.79M
Net Income/Loss:
$-199.61M
P/E Ratio:
-9.0133
EPS:
-3.01
Net Cash Flow:
$-188.48M
1W Performance:
+2.84%
1M Performance:
+10.96%
6M Performance:
+61.10%
1Y Performance:
-13.38%
1-Day Range:
$24.50
$27.40
1-Week Range:
$24.50
$27.98
52-Week Range:
$14.40
$31.66
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
27.13 | 1.78B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | Canaccord Genuity | Buy |
| Mar-20-25 | Initiated | Morgan Stanley | Overweight |
| Feb-13-25 | Initiated | UBS | Buy |
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
Celldex Therapeutics: Caution Warranted After Big Rebound (Rating Downgrade) (NASDAQ:CLDX) - Seeking Alpha
Real time alert setup for Celldex Therapeutics Inc. performanceTrade Exit Summary & Long Hold Capital Preservation Tips - newser.com
Barclays Initiates Celldex Therapeutics at Underweight With $25 Price Target - MarketScreener
Published on: 2025-10-13 01:55:53 - newser.com
Is Celldex Therapeutics Inc. stock a bargain at current levelsJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Best data tools to analyze Celldex Therapeutics Inc. stockTrade Entry Summary & Stepwise Trade Execution Plans - newser.com
Is Celldex Therapeutics Inc. reversing from oversold territoryPortfolio Gains Report & Daily Technical Stock Forecast Reports - newser.com
Chronic Spontaneous Urticaria Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight - Barchart.com
How interest rate cuts could boost Celldex Therapeutics Inc. stockPortfolio Value Report & Daily Stock Momentum Reports - newser.com
Celldex Therapeutics (NASDAQ:CLDX) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Urticaria Pipeline Drugs Insights Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight - Barchart.com
Celldex Bets Big On Its Allergy Pipeline Breakthroughs - Finimize
Analyzing Celldex Therapeutics Inc. with risk reward ratio charts2025 Market Outlook & Weekly High Conviction Ideas - newser.com
Is Celldex Therapeutics Inc. still worth holding after the dip2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com
When is the best time to exit Celldex Therapeutics Inc.2025 Fundamental Recap & Weekly High Momentum Picks - newser.com
Will Celldex Therapeutics Inc. rebound enough to break evenMarket Risk Report & Reliable Intraday Trade Alerts - newser.com
Celldex Therapeutics Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations - Markets Mojo
Celldex Therapeutics (NASDAQ:CLDX) Share Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
How moving averages guide Celldex Therapeutics Inc. trading2025 Institutional Moves & Consistent Growth Stock Picks - newser.com
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200-Day Moving Average – Here’s What Happened - Defense World
Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cu... - ADVFN
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
One Celldex Therapeutics Insider Raised Stake By 40% In Previous Year - 富途牛牛
Sovran Advisors LLC Purchases New Shares in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Mirador Capital Partners LP Raises Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Canaccord Genuity Group Reaffirms Buy Rating for Celldex Therapeutics (NASDAQ:CLDX) - MarketBeat
Technical signs of recovery in Celldex Therapeutics Inc.July 2025 Final Week & Real-Time Stock Price Movement Reports - newser.com
Why Celldex Therapeutics Inc. is moving todayWeekly Stock Analysis & Daily Stock Trend Reports - newser.com
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celldex Therapeutics Inc Stock (CLDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Marucci Anthony S | PRESIDENT & CEO |
Nov 11 '24 |
Buy |
26.82 |
11,500 |
308,430 |
40,284 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):